Salvatore J. Salamone

Salvatore J. Salamone, PhD is Founder, President and CEO of Saladax Biomedical, Inc., an in-vitro diagnostic company that provides proprietary assays that assist with personalized medicine. Dr. Salamone has more than 30 years’ experience in the health care and medical device industries. Prior to founding Saladax in 2004, Dr. Salamone was was Senior Vice President of R&D at OraSure Technologies and Vice President of Research and Development at Roche Diagnostics where he was responsible for North American research and development efforts for the Laboratory Systems Division. During his 17-year tenure at Roche, Dr. Salamone’s efforts resulted in the launch of seven major reagent product lines, 70 FDA-approved products, and more than 200 instrument applications. Dr. Salamone and his current team at Saladax have developed proprietary positions in the field of oncology and psychiatric drug management. These assays address unmet medical needs in providing precision treatment. Dr. Salamone is recognized globally in the field of Therapeutic Drug Monitoring (TDM), having authored more than 80 peer reviewed publications, is the editor of a textbook on benzodiazapines, and is also the holder of 41 issued US patents, in addition to the corresponding international patents. He has received numerous awards, including the Ben Franklin Innovation Award, and in 2016 he was inducted into the prestigious New Jersey Inventors Hall of Fame. Dr. Salamone earned two bachelor’s degrees from Villanova University, a master’s and a PhD degree from Rutgers University and was a Science Engineering Research Council (SERC) Post-Doctoral Fellow at the University of Oxford, UK.
Select Bibliography
* Salamone, S. J. (2010). Benzodiazepines and GHB: Detection and pharmacology. Totowa, NJ: Humana Press.
* Saif MW, Choma A, Salamone SJ, Chu E. Pharmacokinetically guided dose adjustment of 5-fluorouracil: a rational approach to improving therapeutic outcomes. J Natl Cancer Inst. 2009 Nov 18;101(22):1543-52. Review.
* Wilhelm M, Mueller L, Miller MC, Link K, Holdenrieder S, Bertsch T, Kunzmann, V, Stoetzer OJ, Suttmann I, Braess J, Birkmann J, Roessler M, Moritz B, Kraff S, Salamone SJ, Jaehde U. Prospective, Multicenter Study of 5-FluorouracilmTherapeutic Drug Monitoring in Metastatic Colorectal Cancer Treated in Routine Clinical Practice. Clin Colorectal Cancer. 2016 Dec;15(4):381-388 PubMed PMID: 27256667
* Beumer JH, Kozo D, Harney RL, Baldasano CN, Jarrah J, Christner SM, Parise R, Baburina I, Courtney JB, Salamone SJ. An Automated Homogeneous Immunoassay for Quantitating Imatinib Concentrations in Plasma. Ther Drug Monit. 2015 Aug;37(4):486-92. doi: 10.1097/FTD.0000000000000178. PubMed PMID: 25551407; PubMed Central PMCID: PMC4486633.
* Joerger M, Kraff S, Jaehde U, Hilger RA, Courtney JB, Cline DJ, Jog S, Baburina I, Miller MC, Salamone SJ. Validation of a Commercial Assay and Decision Support Tool for Routine Paclitaxel Therapeutic Drug Monitoring (TDM). Ther Drug Monit. 2017 Dec;39(6):617-624. doi: 10.1097/FTD.0000000000000446. .
* Salamone SJ, Jordan F. Synthesis of 9-(3,4-dioxopentyl) hypoxanthine, the first arginine-directed purine derivative: an irreversible inactivator for purine nucleoside phosphorylase. Biochemistry. 1982 Dec 7;21(25):6383-8. PubMed PMID: 6817790.

Main Menu

See Also

Main Menu